← Pharmacyclics, Inc. (PCYC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Pharmacyclics, Inc. (PCYC)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-31 (est.)Phase 3 · Ibrutinibimp 9/10
- 2027-03-18 (est.)Phase 3 · Ibrutinibimp 9/10
- 2027-04-15 (est.)Phase 2 · Ibrutinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Chlorambucil | Phase 3 | Chronic Lymphocytic Leukemia |
| Ibrutinib Oral Capsule | Phase 3 | Follicular Lymphoma |
| PCI-24781 | Phase 2 | Lymphoma |
| MEDI4736 | Phase 2 | Diffuse Large B-Cell Lymphoma |
| Motexafin Gadolinium | Phase 3 | Brain Neoplasms |
| Motexafin Gadolinium Injection | Phase 2 | Multiple Myeloma |
| PCI-27483 | Phase 2 | Pancreatic Cancer |
| MGd | Phase 3 | Metastatic Cancer |
| PCI-32765 | Phase 2 | B-cell Chronic Lymphocytic Leukemia |
| Next-line ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia |
| Ibrutinib | Phase 3 | Diffuse Large B Cell Lymphoma Relapsed |
| ofatumumab | Phase 3 | B-cell Chronic Lymphocytic Leukemia |
| GA101 | Phase 2 | Chronic Lymphocytic Leukemia |
| Ibrutinib 560 mg | Phase 2 | Breast Neoplasms |
| PCI-32765 (Ibrutinib) | Phase 3 | Lymphoma |
| Blinatumomab | Phase 2 | Adult B Acute Lymphoblastic Leukemia |
| Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | Phase 2 | Chronic Lymphocytic Leukemia |
| GCSF | Phase 2 | Sarcoma |
| Fludarabine | Phase 2 | Chronic Lymphocytic Leukemia |
| HD- Methotrexate (MTX) | Phase 2 | Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PCYC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.